A Phase III Case Series Clinical Study of the Reversal of the Anticoagulant Effects of Dabigatran by Intravenous Administration of 5.0g Idarucizumab (BI 655075) in Patients Treated With Dabigatran Etexilate Who Have Uncontrolled Bleeding or Require Emergency Surgery or Procedures.RE-VERSE AD (A Study of the RE-VERSal Effects of Idarucizumab on Active Dabigatran) Trial

Trial Profile

A Phase III Case Series Clinical Study of the Reversal of the Anticoagulant Effects of Dabigatran by Intravenous Administration of 5.0g Idarucizumab (BI 655075) in Patients Treated With Dabigatran Etexilate Who Have Uncontrolled Bleeding or Require Emergency Surgery or Procedures.RE-VERSE AD (A Study of the RE-VERSal Effects of Idarucizumab on Active Dabigatran) Trial

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Apr 2018

At a glance

  • Drugs Idarucizumab (Primary)
  • Indications Blood coagulation disorders; Haemorrhage
  • Focus Registrational; Therapeutic Use
  • Acronyms RE-VERSE AD
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 17 Apr 2018 According to a Boehringer Ingelheim media release, FDA granted Full Approval to Praxbind.
    • 09 Mar 2018 According to a Boehringer Ingelheim media release, data will be presented at the American College of Cardiology (ACC) 67th Annual Scientific Session.
    • 26 Jan 2018 Results of a subanalysis (n=118) assessing the impact of reversal of anticoagulation in a subpopulation of patients with intracranial hemorrhage, presented at the International Stroke Conference 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top